Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Acro Biomedical (ACBM) Interest Expenses (2018 - 2025)

Acro Biomedical (ACBM) has 8 years of Interest Expenses data on record, last reported at $2710.0 in Q3 2025.

  • For Q3 2025, Interest Expenses rose 141.32% year-over-year to $2710.0; the TTM value through Dec 2025 reached $6025.0, up 38.86%, while the annual FY2024 figure was $4339.0, 35.34% up from the prior year.
  • Interest Expenses reached $2710.0 in Q3 2025 per ACBM's latest filing, up from $1948.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $2710.0 in Q3 2025 and bottomed at $178.0 in Q3 2021.
  • Average Interest Expenses over 5 years is $1027.7, with a median of $839.0 recorded in 2023.
  • Peak YoY movement for Interest Expenses: surged 467.57% in 2021, then tumbled 91.65% in 2022.
  • A 5-year view of Interest Expenses shows it stood at $202.0 in 2021, then soared by 289.6% to $787.0 in 2022, then rose by 6.61% to $839.0 in 2023, then soared by 43.62% to $1205.0 in 2024, then skyrocketed by 124.9% to $2710.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Interest Expenses were $2710.0 in Q3 2025, $1948.0 in Q2 2025, and $1367.0 in Q1 2025.